Global Thyroid Gland Disorders: Diagnostics and Treatment Market

Report Highlights

The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

Report Includes

• 97 data tables and 62 additional tables
• An overview of the current and future global markets for thyroid gland disorder
• An analysis of the global market trends with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by type, disease type, end-user industry, and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Analysis of market opportunities from a Porter’s Five Forces perspective, and a value chain analysis considering the prevailing micro- and macro environmental factors
• Coverage of advances in thyroid cancer diagnosis such as genomic tests and treatments, as well as the side effects of current treatments such as radioactive iodine
• Evaluation of ESG practices in the industry, consumer attitudes towards sustainability, risks and opportunity assessment, ratings and matrices
• A patent analysis with emphasis on emerging technologies and new developments in the market
• Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Amgen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bristol-Myers Squibb Co., and Pfizer Inc.

Report Scope

The report analyzes trends in the global market for diagnostics and treatment of thyroid gland disorders. The report includes global revenue ($ million) for the base year 2024, estimated data for 2025, and for the forecast period of 2026 through 2030. The market is segmented by type of disease, product type, end user and region. The disease types are segmented into hypothyroidism, hyperthyroidism, thyroid cancer, and others. Product types are diagnostics and treatments. The diagnostics market is segmented into diagnostic, blood and imaging tests. The treatment market is segmented into medication, thyroid surgery, thyroid eye disease (TED) treatment and other end users are hospitals, specialty clinics, retail and online pharmacies, research and academic institutions, and patient and home care settings. The regions covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW. North American consists of the U.S., Canada, and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

This report focuses on trends and challenges that affect the market, including emerging technologies. It includes an analysis of the competitive landscape, with the rankings and market shares of the leading companies in the global market. The report has a chapter on environmental, social, and corporate governance (ESG) developments and includes company profiles that covers key financials, product portfolios and recent news.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.